SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $10.09M (cash outflow) rose 48.6% year over year, ahead of the +37.8% change in trailing-twelve-month net income. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.
Context
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$22.36M (-16.8%) for the fiscal year ending Dec 2026, a slowdown from the -13.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$10.09M+5.1% QoQ
- Last fiscal yearDec 2025
- -$26.86M-13.0% YoY
- LTMSep 2026
- -$35.76M+37.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.6% | +32.2% | -16.4 pp |
| 1 year | -13.0% | -16.8% | -3.8 pp |
| 3-year CAGR | -13.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (26.86M) USD
- Year-over-year change
- +13.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.86M) | +13.0% |
| FY2024 | 2024-12-31 | (30.88M) | +17.3% |
| FY2023 | 2023-12-31 | (37.34M) | +9.6% |
| FY2022 | 2022-12-31 | (41.3M) | -99.5% |
| FY2021 | 2021-12-31 | (20.7M) | — |
Net Income vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.8% is the 5th highest of 11, against a peer median of +26.5%.
- Over three fiscal years its annual growth of -13.4% compares with a peer median of +19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.61B USD | +85.1% | +55.7% | 27.7% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥1.24B CNY | +212.7% | +11.7% | 221.3% |
| LTM Aug 2026 | $294.88M USD | +220.5% | +13.6% | 42.0% | |
| LTM Sep 2026 | $282.65M USD | +26.9% | +79.2% | — | |
| LTM Mar 2026 | $162.08M USD | +206.1% | +47.5% | 1363.9% | |
| LTM Mar 2026 | $145.24M USD | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $140.06M USD | -54.4% | +24.7% | 62.2% | |
| LTM Mar 2026 | $103.8M USD | +0.5% | -6.4% | 297.8% | |
| LTM Mar 2026 | $77.8M USD | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Sep 2026 | $35.76M USD | +37.8% | -13.4% | — | |
| Peer median (excluding SLS) | — | +26.5% | +19.1% | 141.7% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| Deferred Income Tax | (239K) | (457K) | 0 | 0 | 0 |
| Stock-Based Compensation | 1.01M | 1.73M | 1.39M | 1.56M | 1.96M |
| Change in Working Capital | (7.62M) | 5.64M | 3.35M | (6.65M) | (4.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.51M) | 1.21M | 2.3M | (2.14M) | (535K) |
| Other Working Capital | (5.1M) | 4.43M | 1.04M | (4.51M) | (3.54M) |
| Other Non-Cash Items | 248K | 10.13M | (36.67M) | (30.95M) | 597K |
| Operating Cash Flow | (26.02M) | (23.81M) | (31.41M) | (35.4M) | (28.39M) |
| Capital Expenditures | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.01M | 23.99M | 22.23M | 46.16M | 86.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.07M | 85K | 90K | 594K | (527K) |
| Financing Cash Flow | 12.07M | 24.08M | 22.32M | 46.76M | 86.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.95M) | (4.23M) | (14.6M) | 11.36M | 57.91M |
| Free Cash Flow | (26.02M) | (28.31M) | (36.91M) | (35.4M) | (28.39M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.